Source: Instrument Family, unauthorized reproduction is prohibited, and reprinting is allowed 24 hours later.

In the past year, China's core medical device track — the implantable and interventional device field — has entered a golden period of high-quality development, driven by technological innovation and underpinned by clinical value.

Since its establishment over a decade ago, Instrumentation Family has consistently focused on the fertile ground of China's implant and interventional device sector, personally experiencing and documenting every milestone in this field. Based on thousands of industry updates released in 2025, we concentrated on three core dimensions: "technological innovation breakthrough," "clinical application compatibility," and "industry ecosystem influence." Combining authoritative expert reviews with industry reader feedback through multiple rounds of selection, we ultimately identified the ten most benchmark-worthy innovative implant and interventional products of the year. We are proud to unveil the list: **Instrumentation Family: The Top Ten Implant and Interventional Innovations of 2026**.

*The above list is not ranked in any particular order.

01

Precise and Stable in One Step

WEGO Group: Sedga

Reasons for Selection

Sedga, as the new generation of wide-indication implant system under WEGO Group, inherits the "safe and stable" features of the previous generations of implant systems, while introducing a brand-new concept of precision and controllability to help doctors easily address complex cases such as bone narrowing and insufficient bone height.

Product Introduction

In implant restoration, insufficient bone volume has always been a challenge for clinicians. The WEGO Sedga implant system, with its external cross groove and Morse taper abutment connection design (≤1.5°), achieves a two-piece ultra-narrow (Φ3.0mm) and ultra-short (5.5mm) implant design, providing a "simple, stable, and aesthetically reassuring" one-stop solution for cases of insufficient bone volume.

02

"Large Cavity" Revolution

Kossel: K-Rhino Rhino

Reason for Selection

K-Rhino Rhino™ 14F Large-Lumen Aspiration CatheterExcellent clearance efficiency, fast speed, and high removal rate. Thanks to the large-caliber design, large cavity suction reduces repeated operations, and intraoperative blood loss is controllable. 14F specification, postoperative routine compression can effectively stop bleeding, with good safety.

Product Introduction

K-Rhino Rhino Peripheral Thrombus Aspiration System, featuring 14F large-lumen aspiration, offers four major clinical advantages:

• 14F ultra-large inner diameter, thrombus removal force increased by 1.4 times, suction time significantly reduced, and operation time decreased.
• Large-lumen suction reduces repeated operations, with total blood loss significantly lower than conventional 8F, 10F, and 12F catheters, enhancing surgical safety.
• The management of the 14F puncture site is well-established, and the popliteal vein and femoral vein punctures are safe and effective, with bleeding typically controlled by routine compression.
• Large caliber design for low pressure environments, stable suction efficiency, suitable for diverse surgical scenarios.

03

A New Era of Immediate Implant Placement

Straumann: Straumann® BLX

Reason for Selection

Guided by the concept of aesthetic restoration, the Straumann® BLX series of implants adopts a unified connection method, with streamlined transgingival contour design for restorative components. The entire product series is streamlined yet remains highly flexible and fully functional.

Product Introduction

Straumann®BLX is specifically designed for immediate implant placement with a dynamic bone management feature, enabling minimally invasive and predictable immediate implant solutions in all types of alveolar bone. This implant system upholds the high standards and precision of Swiss quality, incorporating groundbreaking innovative designs supported by long-term scientific evidence, truly allowing dentists to provide treatment with ease, confidence, and assurance.

04

Addressing Challenges in Interventional Radiology

Terumo: Progreat λ® Series Ultrafine Microcatheter

Reason for Selection

The technical breakthrough of Progreat λ® Series Microcatheters marks the official entry of tumor interventional treatment into a refined and personalized era, opening up a completely new technical pathway to enhance the interventional treatment outcomes for tumors such as liver cancer.

Product Introduction

This series of microcatheters achieves significant innovation in core technology: the ultra-fine lumen allows it to easily reach tiny tumor-feeding vessels that traditional catheters struggle to access; excellent trackability ensures smooth navigation through tortuous vessels; stable positioning provides reliable assurance for precise treatment. Particularly noteworthy is its unique variable-diameter design, which maintains the ultra-fine characteristics of the distal end while ensuring overall catheter stability, effectively preventing displacement of the microcatheter tip under high-pressure injection.

In clinical applications, Progreat λ® not only exhibits excellent high-pressure resistance and compatibility with embolic materials but also demonstrates precise super-selective capabilities in handling complex cases such as renal artery ectopic blood supply. It performs exceptionally well in refined TACE combined with particle implantation, immunotherapy, and other comprehensive treatment plans.

05

World's First

Cochlear: Nucleus™ Nexa™ System

Reason for Selection

Nucleus™ Nexa™ System is the world's first intelligent cochlear implant system that applies advanced intelligence and features a powerful chip with high computing and storage capabilities.

Product Introduction

The all-new Nucleus Nexa system represents over a decade of research and development achievements, marking a breakthrough technological innovation in the cochlear implant industry in nearly 20 years by being the first to integrate a smart chip with high computational and storage capabilities into the Nexa implant.

Based on this groundbreaking smart chip platform, Cochlear has pioneered the design of a continuously upgradeable built-in driver software (Firmware), enabling the implant not only to meet current needs but also to evolve with technological advancements. Leveraging robust smart chip technology, it facilitates data exchange between the implant and sound processor, dynamically manages energy release, avoids ineffective energy waste, and achieves high energy efficiency while enhancing hearing performance. Additionally, using advanced smart chip technology, the implant is equipped with intelligent storage of personalized audiograms and tuning parameters, allowing it to seamlessly match new sound processors and ensure users enjoy consistently high-quality auditory experiences.

06

The first and only one in China

Guiling Medical: Quanjing® Bone

Reasons for Selection

Quanjiang® Bone is the first and only calcium sulfate artificial bone product in China to be approved after large-scale clinical trials. Compared with imported calcium sulfate products of the same kind, it has superior clinical performance and a more complete set of accompanying tools, making it a key player in achieving import substitution under the background of national centralized procurement.

Product Introduction

Quanjiang® Bone's main component is high-purity α-crystalline hemihydrate calcium sulfate, with a purity exceeding 98%. Its unique crystal structure design provides a compressive strength more than 6 times that of human cancellous bone and over twice that of imported similar products. After being implanted in areas of bone defect in the human body, it acts as a scaffold material to promote bone repair and regeneration, meeting clinical needs across various fields requiring bone repair such as trauma, joints, spine, and bone tumors.

The product exhibits excellent biocompatibility, capable of complete degradation and absorption by tissues within the patient’s body, achieving a degradation cycle of 2-3 months. The degradation rate aligns closely with the bone regeneration rate. Through process optimization of the material's porous structure, it can quantitatively carry antibiotics, anti-tumor, and anti-tuberculosis drugs, enabling high-concentration, long-acting sustained release over 5-6 weeks. This achieves localized drug delivery for clinical efficacy, reduces adverse reactions, improves drug utilization, and enhances therapeutic effects.

07

First in China, Leading Globally

Jiast: Panshi Biological Type Knee Joint Prosthesis System

Reason for Selection

Compared with traditional cemented prostheses, biological knee prostheses have no risk of cement toxicity or allergic reactions, effectively reduce the incidence of venous thrombosis and aseptic loosening, and avoid soft tissue thermal injury, providing patients with more stable and reliable postoperative recovery.

Product Introduction

The Jiashite Rock Biologic Knee Joint Prosthesis System is an innovative medical device in China. With four major innovative advantages — self-compression mechanical stability technology, zonal trabecular bone design, 3D-printed one-piece molding, and low-friction interface design — this product overcomes the high failure rate issue of traditional non-cemented TKA surgeries. It effectively enhances the immediate stability and long-term bone ingrowth effect of the prosthesis, ensuring faster, more uniform, and firmer bone integration.

08

The World's First

Sino Grand: COMETIU Stent

Reason for Selection

The COMETIU stent is the world's first self-expanding nitinol drug-coated stent system specifically designed for intracranial atherosclerotic stenosis (ICAS) and delivered via a microcatheter. It is also the first neurointerventional device product manufactured in China to receive the U.S. FDA Breakthrough Device Designation.

Product Introduction

In August 2025, COMETIU, a self-expanding intracranial drug-coated stent system independently developed by SinnoMed's subsidiary SinnoChronic, received the FDA Breakthrough Device Designation in the United States.

COMETIU is a closed-loop retrievable stent with excellent wall apposition performance, avoiding the issue of in-stent restenosis caused by open-loop stents tilting inward into the vascular lumen when there is significant residual stenosis. The patented eG™ drug-coated technology ensures optimal drug release after stent implantation: On one hand, it matches the drug concentration in the arterial wall with the proliferation timeline of smooth muscle cells to precisely inhibit excessive smooth muscle cell proliferation; on the other hand, it achieves zero drug residue after 30 days, reducing the inhibition of endothelial cells. This promotes endothelial healing. Additionally, the neurotoxicity of this stent has been verified as safe through animal experiments.

09

The Only One in the World

Baxian An: Iberis® Multi-Polar Renal Artery Radiofrequency Ablation Catheter System

Reasons for Selection

Iberis® Multi-Electrode Renal Artery RF Ablation Catheter System, independently developed by Antong Medical (Biosensors International Group), is the world's only RDN product capable of achieving dual access via both radial and femoral arteries.

Product Introduction

Iberis® Multi-Polar Renal Artery Radiofrequency Ablation Catheter System adopts advanced renal denervation technology. Through minimally invasive intervention, the ablation catheter is accurately delivered to the renal artery vessels, utilizing radiofrequency energy to fully ablate the renal sympathetic nerves, blocking the overactive renal sympathetic nerve signal transmission, bringing new hope and treatment options to a wide range of hypertension patients.

10

First of Its Kind in China

BalRen Medical: SkyMend Pericardial Membrane

Reasons for Selection

SkyMend Pericardial Patch is used for pericardial reconstruction or repair. As the first domestically produced ePTFE (expanded polytetrafluoroethylene) patch product in China, it fills the gap in the research, development, and production technology of ePTFE materials in the country, and is expected to address the long-standing issue of reliance on imported ePTFE implantable devices and materials.

Product Introduction

The ePTFE material used in SkyMend pericardial membranes, sourced from Tianqiong Innovation, a U.S. subsidiary acquired by Bairui Medical, is a material created by stretching standard PTFE (polytetrafluoroethylene) to form a loose microporous structure. Its lightweight, flexible texture and long-term stability within tissue make ePTFE an ideal substitute for pericardial membranes. Extensive research and clinical applications have demonstrated its superior anti-adhesion effects compared to other materials.

——

For a long time, Instrumentation Family has always focused on the cutting-edge technology of the medical device industry, cultivated high-quality resources, and committed to discovering more industry leaders. With a professional perspective, we aim to promote the high-quality development of the industry. In the future, we will continue our efforts and release more innovative lists in various medical device subfields. Stay tuned!